Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;63(2):259-265.
doi: 10.1002/jcph.2158. Epub 2022 Oct 4.

Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program

Kirk Chan-Tack  1 , Mario Sampson  2 , Justin Earp  2 , Vikram Arya  2 , Lynne Yao  3 , John Alexander  3 , Ethan Hausman  3 , Yodit Belew  1 , Debra Birnkrant  1 , Kimberly Struble  1
Affiliations

Considerations and Challenges in the Remdesivir COVID-19 Pediatric Development Program

Kirk Chan-Tack et al. J Clin Pharmacol. 2023 Feb.

Abstract

The US Food and Drug Administration is committed to the development of effective antiviral regimens for pediatric patients with coronavirus disease 2019 (COVID-19), including infants and neonates. On April 25, 2022, the approved indication of remdesivir (RDV) was expanded to include pediatric patients 28 days and older and weighing at least 3 kg with positive results of direct severe acute respiratory syndrome coronavirus 2 viral testing, who are: Hospitalized, or Not hospitalized and have mild to moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death. Given the similar course of COVID-19 in adults and pediatric patients, the approval of RDV for use in pediatric patients is supported by the safety and efficacy data from adequate and well-controlled phase 3 trials in adults and adolescents; and by the safety and pharmacokinetic data from a single-arm, open-label, phase 2/3 pediatric clinical trial of 53 pediatric patients at least 28 days of age and weighing at least 3 kg with confirmed severe acute respiratory syndrome coronavirus 2 infection and mild, moderate, or severe COVID-19. At the time of the April 25, 2022, approval action, the US Food and Drug Administration also revoked the emergency use authorization for RDV that previously covered this pediatric population. This article summarizes key issues and regulatory considerations involved in the RDV COVID-19 pediatric development program, including the evolution of the emergency use authorization issued for RDV as results from registrational studies became available, and discusses lessons learned.

Keywords: COVID-19; antiviral; pediatrics; physiologically based pharmacokinetic modeling.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest to disclose.

References

    1. Code of Federal Regulations Title 21, § 360bbb‐3. Authorization for medical products for use in emergencies. https://www.govinfo.gov/content/pkg/USCODE-2020-title21/pdf/USCODE-2020-.... Accessed June 29, 2022.
    1. Emergency Use Authorization issuance of remdesivir for certain COVID‐19 patients. Issued: May 1, 2020. Reissued: August 28, 2020, October 1, 2020, October 22, 2020, January 21, 2022. https://www.fda.gov/media/137564/download; https://www.fda.gov/media/137565/download; https://www.fda.gov/media/137566/download. Revoked April 25, 2022. Accessed June 29, 2022.
    1. Center for Drug Evaluation and Research . Approval Package and Reviews for NDA 214787; action date, October 22, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214787Orig1s000T.... Accessed June 29, 2022.
    1. Center for Drug Evaluation and Research . Approval Package and Reviews for NDA 214787/Supplement‐10; action date, January 21, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s010.pdf. Accessed June 29, 2022.
    1. Center for Drug Evaluation and Research . Combined Cross‐Discipline Team Leader, Clinical, Clinical Pharmacology, and Division Director Review for NDA 214787/Supplement‐11; action date, April 25, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214787Orig1s011J.... Accessed June 29, 2022.